Apotex announced today that it has launched its generic version of Plavix. Earlier this morning, MarketWatch reported that Bristol-Myers Squibb expected Apotex to launch its generic Plavix shortly. Plavix, a blood thinner, is the second best selling pharmaceutical in the world, with $5.9 billion in annual sales.
Apotex is currently in patent litigation with Bristol-Myers Squibb and sanofi-aventis over its generic Plavix. By launching its product before that litigation has been decided, Apotex is taking a huge risk that it will win the case. If it loses, Apotex may be on the hook for billions of dollars in patent infringement damages.
Thanks to David Fischer of The Antitrust Review for alerting me to this news!
RELATED READING:
- Wall Street Journal Online story about Apotex's launch
- related Apotex press releases
- 08-Aug-06 sanofi-aventis press release
Comments